Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Your doctor or oncologist may prescribe Fulphila if you have a non-myeloid malignancy, are receiving chemotherapy to suppress the immune system, and have clinically significant febrile neutropenia. Febrile neutropenia is when white blood cells are low, and there is a fever. These symptoms indicate that the person has an infection but their immune system is not strong enough to fight it.
Fulphila contains pegfilgrastim, which is a pegylated form of naturally occurring granulocyte colony-stimulating factors (G-CSF). Fulphilka binds to bone marrow cells, augmenting their growth and replication. Binding to bone marrow cells leads to an increase in neutrophils, fortifying the body's defense against infections and restoring immune system function.
The recommended dosage of Fulphila is 6 mg administered as a single subcutaneous injection per chemotherapy cycle. The timing and frequency may vary based on the specific chemotherapy regimen and individual patient characteristics.
Do not stop or change your treatment without speaking to your oncologist.
The active ingredient in Fulphila is pegfilgrastim.
White blood cells should be closely monitored while taking this drug.
Stop Fulphila if breathing\ trouble occurs, because it could mean a hypersensitivity reaction or acute respiratory distress syndrome (ARDS).
Patients with a personal or family history of sickle cell disease or kidney disease should inform their doctors before starting this medication.
Fulphila should not be administered 14 days before or 24 hours after cytotoxic chemotherapy.
Pediatric patients receive a weight-based dose.
Immediate medical attention is needed for symptoms such as left upper abdominal or shoulder pain, indicative of a potential enlarged spleen or splenic rupture.
Common adverse reactions to this drug may include:
Fulphila [package insert]. Zurich, Switzerland: Mylan; June 2018.